Key result
Personalized management of intrinsic susceptibility and acquired triggers maintains HF remission in DCM.
Why the study?
Once remission of heart failure has been achieved in patients with dilated cardiomyopathy, it remains unclear which treatments need to be continued long term.
Highlights the need for personalized therapy and evidence from randomized trials to guide long-term treatment in patients with dilated cardiomyopathy who have achieved heart failure remission.
May support personalized therapy to sustain dilated cardiomyopathy remission; leaves open optimal strategies pending randomized trials.
Remission of heart failure, defined by resolution of symptoms, normalization of left ventricular ejection fraction, and plasma concentrations of natriuretic peptides and by the ability to withdraw diuretic agents without recurrence of congestion is increasingly recognized among patients with dilated cardiomyopathy. Once remission has been achieved, it is unclear which treatments need to be continued long term. The durability of remission and likelihood of relapse are likely to be determined by intrinsic myocardial susceptibility, the persistence or recurrence of any acquired triggers, and current and future myocardial workload. Each of these should be addressed to enable personalized therapy to delay or prevent relapse. Management should be informed by evidence from randomized trials of targeted therapeutic strategies.
No takes yet. Share an insight, caveat, or question.
Halliday et al. (2022) conducted a review in Dilated cardiomyopathy and remission of heart failure. Maintaining heart failure remission in patients with dilated cardiomyopathy requires personalized management of intrinsic myocardial susceptibility and acquired triggers to prevent relapse.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: